Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
31000 participants
OBSERVATIONAL
2002-01-31
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Practically all patients undergoing cardiac surgery in Finland have a blood product booking from the Finnish Red Cross Blood Service. This registry contains large volumes of transfusion-related information on all Finnish patients undergoing cardiac surgery in Finnish centers. Participating hospitals were scattered to all geographical areas in Finland and concentrated to the most populated regions.
Data on the blood product use, laboratory findings one month pre-operatively and 12 months post-operatively were available.
Finnish hospitals have been required to provide information on hospital visits for the Finnish National Research and Development Centre for Welfare and Health for healthcare planning purposes. We used in part the original data sent by hospitals to the Finnish Hospital Discharge Register (FHDR).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Conservation in Cardiac Surgery
NCT01463345
Balancing Risk: Red Blood Cell Transfusion Strategies In Cardiac Surgery
NCT00651573
Advance Targeted Transfusion in Anemic Cardiac Surgical Patients for Kidney Protection: A Proof of Concept Pilot Study
NCT00861822
Patient Blood Management in Cardiac Surgery
NCT04040023
Hemostatic Effects of Ulinastatin and Tranexamic Acid in Cardiac Surgery
NCT01060189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* \>21 000 patients who underwent coronary bypass,
* \>4500 patients with aortic valve replacement,
* \>4000 mitral valve operation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardiac surgery
Patients who have undergone cardiac surgery
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Blood product booking for surgery
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Finnish Red Cross Blood Service
OTHER
Central Finland Hospital District
OTHER
Turku University Hospital
OTHER_GOV
Oulu University Hospital
OTHER
Tampere University Hospital
OTHER
Kuopio University Hospital
OTHER
Helsinki University Central Hospital
OTHER
Satakunta Central Hospital
OTHER
University of Turku
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Pirjo Mustonen, MD, PhD
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pirjo Mustonen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Central Finland Central Hospital
Juhani Airaksinen, Prof
Role: PRINCIPAL_INVESTIGATOR
Turku University Hospital and University of Turku
Fausto Biancari, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Oulu University Hospital
Tuomas O Kiviniemi, Md, PhD
Role: PRINCIPAL_INVESTIGATOR
Turku University Hospital and University of Turku
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BiCS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.